Aptatargets

AptaTargets is a clinical-stage biopharmaceutical company that develops therapeutic applications based on aptamer technology. The company focuses on treating acute indications where inflammation causes significant damage, such as ischemic stroke, myocardial infarction, and multiple sclerosis. Its lead candidate, ApTOLL, is a neuroprotective drug designed to block TLR4 activation during the acute phase of a stroke.